PJ Chen
CEO
CB
Cali Biosciences
Cali Biosciences develops innovative perioperative drugs, including anesthetics, analgesics, and anti-inflammatories, targeting unmet needs in global markets. Their pipeline focuses on complex injectable formulations with high technological barriers to entry, seeking regulatory approval in China, the US, and the EU. The company aims to improve patient outcomes and quality of life through novel pharmaceutical solutions.
- Biotechnology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Post-operative pain management often relies on opioid analgesics, which carry significant risks of addiction and adverse side effects. Traditional local anesthetics like ropivacaine have a limited duration of action, requiring frequent dosing or catheter-based delivery for prolonged pain relief after surgery.
Solution
Cali Biosciences is developing innovative, non-opioid solutions for perioperative pain management, including CPL-01, a long-acting ropivacaine formulation. CPL-01 utilizes the proprietary PG-Depot technology platform to extend the duration of analgesic effects, providing consistent and predictable release of ropivacaine for up to 72 hours after a single administration. This extended release reduces the need for opioids and frequent dosing, offering a more convenient and patient-friendly solution for post-operative pain control. Phase 2 clinical trials have demonstrated that CPL-01 reduces post-operative pain intensity scores and decreases reliance on opiate analgesics compared to placebo, while exhibiting a positive safety profile. The company has initiated Phase 3 clinical trials in the United States for open inguinal herniorrhaphy and bunionectomy.
Target Audience
The primary target audience includes surgeons, anesthesiologists, and pain management specialists seeking non-opioid alternatives for post-operative pain control, as well as hospitals and surgical centers aiming to improve patient outcomes and reduce opioid-related complications.
Features
- Extended-release injectable formulation of ropivacaine hydrochloride
- Utilizes the PG-Depot technology platform for prolonged duration of action
- Provides consistent and predictable release of ropivacaine for up to 72 hours
- Demonstrated reduction in post-operative pain intensity scores in Phase 2 trials
- Shown to decrease reliance on opiate analgesics compared to placebo
- Currently in Phase 3 clinical trials for open inguinal herniorrhaphy and bunionectomy
- Designed for single local administration, eliminating the need for analgesic pumps or catheters